Short Communication

Transcriptional Silencing of the TFPI-2 Gene by Promoter Hypermethylation in Choriocarcinoma Cells

Florent Hubé¹, Pascale Reverdiau^{1,*},
Sophie lochmann¹, Jérôme Rollin¹,
Catherine Cherpi-Antar² and Yves Gruel¹

¹ Laboratoire d'Hémostase, EA 3249 'Cellules
Hématopoïétiques, Hémostase et Greffe',

² Laboratoire de Biochimie et de Biologie Moléculaire,
INSERM U316, Faculté de Médecine,
IFR 120 'Imagerie et Exploration fonctionnelles', 2bis
Boulevard Tonnellé, F-37032 Tours cedex, France

*Corresponding author

Tissue factor pathway inhibitor-2 (TFPI-2), a Kunitz-type serine proteinase inhibitor associated with the extracellular matrix, has been shown to reduce tumor invasion. In the present study we identified the presence of a complete CpG island region spanning exon 1 and the three transcription initiation sites. We demonstrate that DNA demethylation by 5'-aza-2'-deoxycytidine restores TFPI-2 transcription in JAR choriocarcinoma cells. The effect of *in vitro* DNA methylation on TFPI-2 promoter function was also confirmed with TFPI-2/luciferase promoter constructs. Finally, we determined the precise methylation status of CpG sites of the TFPI-2 promoter in normal and tumor trophoblast cells using the bisulfite genomic sequencing method. We conclude that hypermethylation of the TFPI-2 gene is correlated with transcriptional silencing and that the TFPI-2 gene may be a candidate tumor suppressor gene.

Key words: 5'-Aza-2'-deoxycytidine/JAR cells/
Methylation status/Normal trophoblast cells/Tissue
factor pathway inhibitor 2/Transcriptional silencing.

The degradation of the extracellular matrix (ECM) is an important step in tumor invasion and metastasis which involves a variety of proteases, particularly metalloproteinases (MMPs). Tissue factor pathway inhibitor-2 (TFPI-2), a 32 kDa Kunitz-type serine proteinase inhibitor associated with the ECM, was recently shown to reduce tumor invasion. By inhibiting plasmin and trypsin, TFPI-2 effectively decreases activation of MMP-1, MMP-3, MMP-9 and MMP-13 (Rao *et al.*, 1999; Herman *et al.*, 2001), thus reducing the invasive potential of several tumor cell lines (Rao *et al.*, 1998, 2001; Konduri *et al.*, 2000, 2001). The promoter of the human TFPI-2 gene, which is

located on chromosome 7q22 (Miyagi *et al.*, 1996), has been characterized, and we identified a complete CpG island region of at least 220 bp that spans exon 1 and the three transcription initiation sites. This region, with a G+C content of about 77% and an observed/expected presence of CpG>0.85, also coincides with the 5'-end of the minimal promoter. We therefore hypothesized that the TFPI-2 gene promoter could be regulated by DNA methylation and that the TFPI-2 gene might be a candidate tumor suppressor gene. CpG islands are protected from methylation in normal cells by mechanisms that are poorly understood. In contrast, hypermethylation of CpG islands in the promoter region of tumor suppressor genes is a known mechanism of gene silencing that contributes to tumor progression. We have reported recently that TFPI-2 transcripts are synthesized in large amounts in normal trophoblast cells isolated from term placentas (Hubé *et al.*, 2003a), whereas they were not detected in invasive human JAR choriocarcinoma cells (Jin *et al.*, 2001; lochmann *et al.*, 2002) either stimulated by phorbol myristate acetate (PMA) or left unstimulated. In the present study we investigated whether the methylation status of the human TFPI-2 gene promoter could regulate the level of expression of TFPI-2 in trophoblast cells. We therefore tested the effects of 5'-aza-2'-deoxycytidine (5-aza) on the reactivation of TFPI-2 transcription in JAR cells following DNA demethylation. The effects of *in vitro* DNA methylation on TFPI-2 promoter function were also confirmed with TFPI-2/luciferase promoter constructs (TFPI-2/Luc). Finally, we determined the methylation status of the human TFPI-2 gene promoter in normal trophoblast cells and JAR choriocarcinoma cells using the bisulfite genomic sequencing method.

TFPI-2 mRNA synthesis was studied in normal trophoblast and JAR choriocarcinoma cells using a specific RT-PCR method. PMA, an inducer of TFPI-2 expression, was used at optimal concentration (100 ng/ml) and incubation time (4 h) as previously defined (lochmann *et al.*, 2002). The RT-PCR product obtained appeared as a single band of 253 pb, the expected size of the TFPI-2 cDNA product, and sequencing yielding a result similar to the previously published sequence (Sprecher *et al.*, 1994) confirmed the specificity of the technique. Expression of GAPDH used as a control was not affected in any experiment.

A large amount of TFPI-2 mRNA was detected in normal trophoblast cells, and the levels increased after stimulation with PMA (Figure 1A). In contrast, TFPI-2 mRNA

Fig. 1 TFPI-2- and GAPDH-Specific RT-PCR in Normal Trophoblast cells (TC), Choriocarcinoma Cells (JAR) and JAR Cells Treated with 5'-Aza-2'-Deoxycytidine (JAR + 5-aza).

Term placentas were supplied following spontaneous vaginal delivery in uncomplicated pregnancies after obtaining informed consent. Trophoblast cells were isolated (Hubé *et al.*, 2003a) and grown in Waymouth/Ham's F12 medium (v/v) supplemented

with 17% endotoxin-free heat-inactivated fetal calf serum (FCS, ATGC Biotechnologie, Noisy le Grand, France). The human JAR cell line was obtained from the American Type Culture Collection (Rockville, MD, USA) and grown in RPMI-1640 medium (Invitrogen, Cergy Pontoise, France) supplemented with 10% FCS. To assess reactivation of TFPI-2 expression in JAR cells, cells were treated for 48 h with 1 μ M 5-aza (Sigma Aldrich Chimie, Saint Quentin Fallavier, France) and then for 48 h with freshly prepared medium containing 5 μ M 5-aza. All cells were unstimulated (US) or stimulated with 100 ng/ml PMA for 4 h (PMA). Total mRNA was isolated from 2×10^5 trophoblast cells stimulated with PMA or left unstimulated using the Dynabeads mRNA Direct kit (Dynal France SA, Compiègne, France) according to the manufacturer's instructions. Total mRNA (40 ng for 2×10^5 cells) was then reverse transcribed as previously described (Iochmann *et al.*, 2002). PCR was performed using first-strand cDNA obtained from 5×10^4 cells and 1 μ M of forward and reverse oligonucleotide primers (Genset SA, Paris, France) specific for TFPI-2 or GAPDH. PCR carried out for 35 cycles (94°C for 30 s, 62°C for 30 s and 72°C for 30 s) and RT-PCR products were sequenced on both strands with the reverse and forward primers on a Perkin Elmer ABI Prism™ 377 DNA sequencer. RT-PCR products were analyzed by electrophoresis through 1.6% agarose gels containing 1 μ g/ml ethidium bromide. Lane M, ϕ X174 RF DNA/HaeII DNA ladder; *, negative control (PCR without DNA). Data are representative of at least three independent experiments.

Fig. 2 Inhibition of Human TFPI-2 Promoter Activity by SssI Methyltransferase.

Various deletion constructs of the 5'-flanking region of the

TFPI-2 gene promoter were generated by PCR using modified primers containing restriction enzyme recognition sites (Table 1). The *Xho*I and *Hind*III restriction enzyme-digested fragments obtained (2257, 534, 260 and 124 bp) were subsequently subcloned in the promoter/enhancerless expression vector pGL3-Basic (Promega, Charbonnières, France) upstream from the luciferase reporter gene and all promoter constructs (T1, T2, T3 and T4, respectively) were sequenced on both strands. The TFPI-2/luciferase reporter constructs (TFPI-2/Luc) were methylated using SssI methyltransferase for 16 h at 37°C in NEBuffer 2 (New England Biolabs Ltd, Oly, UK) containing 180 μ M S-adenosylmethionine, 10 units of SssI methyltransferase and 5 μ M of plasmids. The reactions were terminated by heating for 15 min at 65°C. Complete methylation of constructs was checked by evaluating their resistance to cleavage by *Bst*UI restriction endonuclease (New England Biolabs). Only plasmids that were completely resistant to digestion were then used in the transfection experiments. (A) Schematic map of the fragments T1 to T4. (B) *Bst*UI digestion of human TFPI-2/Luc before (-) and after (+) SssI treatment. Digestion products were analyzed by electrophoresis through 1.6% agarose gel containing 1 μ g/ml ethidium bromide. Lane M, 1 kb ladder of DNA size marker containing DNA fragments ranging from 75 to 12 216 bp. (C) The un-methylated (white) and methylated (black) human TFPI-2/Luc (1.1 μ M) and plasmid controls were transiently transfected into the JAR choriocarcinoma cell line using LipofectAMINE Plus™ Reagent (Invitrogen) according to the manufacturer's instructions. The β Gal plasmid (pSVbeta-galactosidase control vector, Promega) was always co-transfected to normalize transfection efficacy. Cells were harvested 24 h after transfection, and luciferase activity was measured using a Wallac Victor 2 multilabel reader luminometer (Perkin Elmer, Le Blanc Mesnil, France) and expressed in relative light units (RLU). A positive control containing CMV promoter sequence (pGL3 control) and a negative control (pGL3-Basic) were used for each experiment. Data are the mean $\pm$ SEM of at least three independent transfections.

was not detected in JAR cells, even after incubation with PMA for 4 h. These results demonstrate a discrepancy in TFPI-2 mRNA expression between normal and tumor cells, and we hypothesized that TFPI-2 gene expression is repressed in JAR cells. We therefore analyzed the TFPI-2 gene promoter sequence and identified a complete CpG island region that spans exon 1 and the three transcription initiation sites. This finding suggests that the methylation status of the human TFPI-2 gene promoter could regulate the level of expression of TFPI-2 in trophoblast cells.

To demonstrate that hypermethylation of the TFPI-2 gene is responsible for the downregulation of TFPI-2 mRNA synthesis in JAR cells, we treated cells with 5-aza, a demethylating agent that has been shown to reactivate the expression of many genes in several tumor cell lines (Guillaud *et al.*, 1995; Hanski *et al.*, 1997; Christman, 2002). After treatment with 5-aza, TFPI-2 mRNA synthesis was restored in JAR choriocarcinoma cells (Figure 1B), which was probably related to the decreased methylation status of the TFPI-2 5'-flanking region. In addition, TFPI-2 mRNA expression was increased when 5-aza-treated JAR cells were incubated with PMA, whereas JAR cells without 5-aza treatment did not express TFPI-2 (Figure 1A). The DNA methylation status might affect the ability of transcription factors involved in the PMA-dependent signaling pathway to bind to their recognition sites, as previously demonstrated for AP-2, c-Myc, CREB and NF- κ B (Bergman et Mostoslavsky, 1998).

The effects of *in vitro* DNA methylation on TFPI-2 promoter function were also confirmed with TFPI-2/Luc methylated *in vitro* with SssI methyltransferase which recognizes CpG sites. Total methylation was confirmed by resistance to cleavage with BstUI restriction endonuclease. The promoter constructs used were previously described (Hubé *et al.*, 2003b) and contained promoter sequences -2299/-42 (T1), -576/-42 (T2), -302/-42 (T3) and -166/-42 (T4) from the translation start site, comprising transcription factor binding sites necessary for transcriptional activity. Methylated or unmethylated TFPI-2/Luc plasmids were then transiently transfected into JAR cells and the luciferase activity of each promoter deletion construct (normalized with β Gal values) was compared to that of the pGL3 positive control.

Figure 2A shows that no band smaller than 5 kb was detected in agarose gels (lanes 2, 4, 6 and 8), demonstrating the efficiency of SssI methyltransferase treatment with all plasmid constructs. Indeed, only completely methylated plasmids were resistant to digestion with methylation-sensitive BstUI restriction endonuclease and were then used in the transfection experiments.

The luciferase activity of each promoter construct was abolished after methylation with SssI, in contrast to the activity of unmethylated constructs (Figure 2B). Moreover, hypermethylation of the T4 construct that we previously defined as the minimal promoter (Hubé *et al.*, 2003b) greatly decreased luciferase activity. These results indicate that hypermethylation of the CpG island

Table 1 Oligonucleotide Primers Used in This Study.

Primer set	Sense primer sequence (5'-3')	Genomic position	Antisense primer sequence (5'-3')	Genomic position	Product size (bp)	Assay ^a
T4/T2a	ACAGTCCCTCGAGCATGAATCAGCCAC	-176/-151	CAAGCTTGGCAAGCGTCCGAGAAAGC	-20/-46	124	PC
T3/T2a	CATTACTGACTCGAGCGCTCCCTCAG	-314/-289	CAAGCTTGGCAAGCGTCCGAGAAAGC	-20/-46	260	PC
T2/T2a	CTGTCCACCCCTCGAGATATTATAAGCCTG	-588/-560	CAAGCTTGGCAAGCGTCCGAGAAAGC	-20/-46	534	PC
T1/T2a	CTGGCTGTCTGTCTCGAGGGTTGGTGC	-2313/-2287	CAAGCTTGGCAAGCGTCCGAGAAAGC	-20/-46	2257	PC
MSP1/MSP2	TAGGAGTTTTTTGGAGTGATGGAAT	-996/-971	CACCTTAAAAAACCCAAACTAAACCTCC	+658/+686	1682	BGS
MSP3/MSP4	GGATTATAGGAGAAAGTTTGGGAGGTAGG	-275/-247	CAACATCCTCCCAATACAACTCC	+50/+81	356	BGS
MSP5/MSP6	ATATAGTTTGTAGYGGGGGYG	-207/-183	CAAAAAAACAAATCRACACCC	+21/+48	255	BGS

^aPrimers used for plasmid construction (PC) and for bisulfite genomic sequencing (BGS). The XhoI and HindIII restriction sites are underlined; bold letters indicate mutated nucleotides.

within the minimal promoter is sufficient to affect TFPI-2 expression, in agreement with previous studies that indicated a correlation between CpG methylation of the minimal promoter and transcriptional silencing (Singal *et al.*, 1997; Kinoshita *et al.*, 2000).

Bisulfite genomic sequencing was used to determine precisely the methylation status of each CpG dinucleotide within a 250 bp region of the TFPI-2 gene promoter. The sodium bisulfite treatment converts unmethylated cytosines to uracil residues, while 5-methylcytosines remain unmodified. Sequencing the PCR products of bisulfite-treated DNA allows a determination of the methylation profiles of individual DNA molecules. Twenty-eight putative CpG sites were studied in a TFPI-2 region of about 250 bp (–207/+48 from the translation start site) which spanned the three transcription initiation sites and the translation start site and included the TFPI-2 minimal promoter. After amplification by nested PCR using modified primers (Table 1), PCR products were sequenced on both strands and the percentage of cytosine methylation was

calculated as the number of methylated cytosines divided by the number of putative CpG dinucleotides. Figure 3 shows that 97.5% of 24 CpG sites were methylated in JAR cells that did not express TFPI-2 mRNA. By contrast, the CpG island was found to be poorly methylated (6.3% of 28 CpG's) in normal trophoblast cells that synthesized large amounts of TFPI-2 mRNA. Interestingly, methylation of the promoter region of JAR cells treated with 5-aza was 51.3%, with two regions particularly hypomethylated (CpG 12–18 and CpG 24–27) and two regions hypermethylated (CpG 4–11 and CpG 19–23). Significant TFPI-2 mRNA synthesis was observed in 5-aza-treated cells but remained lower than that of normal trophoblast cells. These results strongly support the hypothesis that, as previously demonstrated for several other genes (Hanski *et al.*, 1997; Esteller, 2002), hypermethylation of CpG sites of the TFPI-2 promoter is correlated with the transcriptional repression of this gene in JAR choriocarcinoma cells.

In addition, our results with JAR 5-aza cells suggest

Fig. 3 Methylation Analysis of the TFPI-2 Gene Promoter.

The CpG methylation status of a 250 bp region (–207/+48 from translation start site) of the TFPI-2 promoter was studied by bisulfite genomic sequencing in untreated choriocarcinoma cells (JAR), JAR cells treated with 5-aza (JAR + 5-aza) and normal trophoblast cells (TC). Genomic DNA was isolated from cells using the DNeasy Tissue kit (Qiagen, Courtaboeuf, France) and converted using sodium bisulfite conversion, following the protocol of Frommer *et al.* (1992) with minor modifications. Briefly, 4 µg of DNA was digested overnight with 5 units of *HindIII*. Digested DNA was purified through columns of the GFX PCR DNA and Gel Purification Kit (Amersham Pharmacia Biotech Europe GMBH, Paris, France) and then denatured in 0.3 M NaOH supplemented with 10 µg tRNA (Sigma Aldrich Chimie) for 20 min at 42 °C. Sodium bisulfite solution generated by sodium metabisulfite (Sigma Aldrich Chimie) was added at a final concentration of 3 M, layered with mineral oil and incubated for 16 h at 50 °C in the dark with 20 mM hydroquinone, pH 5.0. DNA was desalted with the GFX PCR DNA and Gel Purification Kit, desulfonated with 0.3 M NaOH, and ethanol precipitated. DNA was then amplified using nested PCR. The first reaction used about 80 ng of bisulfite-modified DNA, outer modified primers (Table 1) and was carried out for 35 cycles (94 °C for 30 s, 60 °C for 30 s and 72 °C for 60 s). The nested PCR reactions were performed using a 25-fold dilution of PCR products with inner modified primers (Table 1). PCR products were then purified and sequenced, and the sequences were analyzed by comparing them with the original sequences. Numbers at the top (1 to 28) correspond to the relative position of CpG sites in this region. Major (MIS) and minor transcription initiation sites (mIS) are indicated. Each row of circles represents a single PCR product which was sequenced on both strands and each circle represents a single CpG site (open circles, non-methylated cytosines; filled circles, methylated cytosines). Results were obtained from at least three independent DNA extractions and bisulfite conversions.

that unmethylated regions between -112/-63 and -18/+14 (CpG 12-18 and 24-27) may allow TFPI-2 transcription initiation in this cell line. Moreover, hypermethylation of regions between -183/-113 and -54/-20 (CpG 4-11 and 19-23) appeared necessary but not sufficient to suppress TFPI-2 synthesis. Interestingly, the region between -112/-63, which was demethylated after 5-aza treatment, contains the major transcription initiation site previously identified at position -75 upstream from the translation start site (Hubé *et al.*, 2003b). Additional data on other tumoral cell lines will be necessary to verify the importance of these regions in TFPI-2 gene transcription.

In conclusion, the present study shows that among the multiple mechanisms that could regulate TFPI-2 expression, hypermethylation of the promoter region CpG island is a likely epigenetic modification. This mechanism might in choriocarcinoma contribute to a decrease in TFPI-2 synthesis, thereby favoring cancer invasion. Lakka *et al.* (2000) demonstrated that the downregulation of TFPI-2 with an antisense strategy increased the invasiveness of lung cancer cells. Moreover, another study showed that the transfection of JAR choriocarcinoma cells with a TFPI-2 expression vector reduced their invasive potential *in vitro* and *in vivo* (Jin *et al.*, 2001). Further studies are necessary to verify the significance of TFPI-2 gene inactivation in choriocarcinomas from patients.

Acknowledgments

We are grateful to Prof. G. Body and Prof. F. Perrotin (Département de Gynécologie et Obstétrique, CHRU de Tours, France) who provided term placentas. We particularly thank Antoine Touzé (EMI-U0010, Tours) for the gift of pGL3 positive control. We also thank D. Raine for editing the English. This study was supported by the Ligue Contre Le Cancer and IRTN.

References

- Bergman, Y., and Mostoslavsky, R. (1998). DNA demethylation: turning genes on. *Biol. Chem.* 379, 401-407.
- Christman, J.K. (2002). 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. *Oncogene* 21, 5483-5495.
- Esteller, M. (2002). CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. *Oncogene* 21, 5427-5440.
- Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L., and Paul, C.L. (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc. Natl. Acad. Sci. USA* 89, 1827-1831.
- Guillaudeux, T., Rodriguez, A.M., Girr, M., Mallet, V., Ellis, S.A., Sargent, I.L., Fauchet, R., Alsat, E., and Le Bouteiller, P. (1995). Methylation status and transcriptional expression of the MHC class I loci in human trophoblast cells from term placenta. *J. Immunol.* 154, 3283-3299.
- Hanski, C., Riede, E., Gratchev, A., Foss, H.D., Bohm, C., Klusmann, E., Hummel, M., Mann, B., Buhr, H.J., Stein, H., Kim, Y.S., Gum, J., and Riecken, E.O. (1997). MUC2 gene suppression in human colorectal carcinomas and their metastases: *in vitro* evidence of the modulatory role of DNA methylation. *Lab. Invest.* 77, 685-695.
- Herman, M.P., Sukhova, G.K., Kisiel, W., Foster, D., Kehry, M.R., Libby, P., and Schonbeck, U. (2001). Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. *J. Clin. Invest.* 107, 1117-1126.
- Hubé, F., Reverdiau, P., Iochmann, S., Trassard, S., Thibault, G., and Gruel, Y. (2003a). Demonstration of tissue factor pathway inhibitor-2 (TFPI-2) mRNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas. *Biol. Reprod.* 68, 1888-1894.
- Hubé, F., Reverdiau, P., Iochmann, S., Cherpi-Antar, C., and Gruel, Y. (2003b). Characterization and functional analysis of TFPI-2 gene promoter in a human choriocarcinoma cell line. *Thromb. Res.* 109, 207-215.
- Iochmann, S., Reverdiau-Moalic, P., Hubé, F., Bardos, P., and Gruel, Y. (2002). Demonstration of inducible TFPI-2 mRNA synthesis in BeWo and JEG-3 trophoblast cells using a competitive RT-PCR. *Thromb. Res.* 105, 217-223.
- Jin, M., Udagawa, K., Miyagi, E., Nakazawa, T., Hirahara, F., Yasumitsu, H., Miyazaki, K., Nagashima, Y., Aoki, I., and Miyagi, Y. (2001). Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells *in vitro* and *in vivo*. *Gynecol. Oncol.* 83, 325-333.
- Kinoshita, H., Shi, Y., Sandefur, C., Meisner, L.F., Chang, C., Choon, A., Reznikoff, C.R., Bova, G.S., Friedl, A., and Jarrard, D.F. (2000). Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. *Cancer Res.* 60, 3623-3630.
- Konduri, S.D., Tasiou, A., Chandrasekar, N., Nicolson, G.L., and Rao, J.S. (2000). Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. *Clin. Exp. Metastasis* 18, 303-308.
- Konduri, S.D., Rao, C.N., Chandrasekar, N., Tasiou, A., Mohanam, S., Kin, Y., Lakka, S.S., Dinh, D., Olivero, W.C., Gujrati, M. *et al.* (2001). A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. *Oncogene* 20, 6938-6945.
- Lakka, S.S., Konduri, S.D., Mohanam, S., Nicolson, G.L., and Rao, J.S. (2000). *In vitro* modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. *Clin. Exp. Metastasis* 18, 239-244.
- Miyagi, Y., Yasumitsu, H., Eki, T., Miyata, S., Kkawa, N., Hirahara, F., Aoki, I., Misugi, K., and Miyazaki, K. (1996). Assignment of the human PP5/TFPI-2 gene to 7q22 by FISH and PCR-based human/rodent cell hybrid mapping panel analysis. *Genomics* 35, 267-268.
- Rao, C.N., Cook, B., Liu, Y., Chilukuri, K., Stack, M.S., Foster, D.C., Kisiel, W., and Woodley, D.T. (1998). HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. *Int. J. Cancer* 76, 749-756.
- Rao, C.N., Mohanam, S., Puppala, A., and Rao, J.S. (1999). Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. *Biochem. Biophys. Res. Commun.* 255, 94-98.
- Rao, C.N., Lakka, S.S., Kin, Y., Konduri, S.D., Fuller, G.N., Mohanam, S., and Rao, J.S. (2001). Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. *Clin. Cancer Res.* 7, 570-576.
- Singal, R., Ferris, R., Little, J.A., Wang, S.Z., and Ginder, G.D.

- (1997). Methylation of the minimal promoter of an embryonic globin gene silences transcription in primary erythroid cells. *Proc. Natl. Acad. Sci. USA* **94**, 13724–13729.
- Sprecher, C.A., Kiesel, W., Mathewes, S., and Foster, D.C. (1994). Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. *Proc. Natl. Acad. Sci. USA* **91**, 3353–3357.

Received January 15, 2003; accepted March 3, 2003